This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.

─────────────────────────────────────────
Beyonttra is indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM)
─────────────────────────────────────────
PP-BEY-GB-0001 | May 2025
- Referencesexpand_less
- 1UK Summary of Product Characteristics for BEYONTTRA (acoramidis)